Top

Published in:

07-07-2023 | Clostridioides Difficile | Disease Management

Consider new therapies for the treatment and prevention of Clostridioides difficile infection

Authors: Caroline Fenton, Connie Kang

Published in: Drugs & Therapy Perspectives | Issue 7/2023

Abstract

New therapies to treat and prevent Clostridioides difficile infections (CDI) are needed. CDI requires antibiotic therapy, but this can disrupt gut microbiomes and increase susceptibility to recurrent CDI (rCDI). The search for narrow spectrum, microbiome-sparing antibiotics that can eliminate CDI has been challenging. However, three agents are approved for the prevention of rCDI, including the monoclonal antibody bezlotoxumab and two human donor stool products (rectally administered REBYOTA^TM and oral VOWST^TM).

Gonzales-Luna AJ, Carlson TJ, Garey KW. Emerging options for the prevention and management of Clostridioides difficile infection. Drugs. 2023;83(2):105–16.CrossRefPubMedPubMedCentral

Jou J, Ebrahim J, Shofer FS, et al. Environmental transmission of Clostridium difficile: association between hospital room size and C. difficile infection. Infect Control Hosp Epidemiol. 2015;36(5):564–8.CrossRefPubMedPubMedCentral

Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol. 2022;20(5):285–98.CrossRefPubMed

Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124–47.CrossRefPubMed

Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–44.CrossRefPubMed

Van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27(Suppl. 2):S1-24.CrossRefPubMed

Okhuysen PC, Ramesh M, Garey K, et al. A phase 3, randomized, double-blind study to evaluate the efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridioides difficile infection [abstract no. 730]. Open Forum Infect Dis. 2022;9(Suppl. 2):ofac492.021.CrossRef

Crestone Inc. CRS3123 for C. difficile infection. 2022. https://crestonepharma.com. Accessed 31 May 2023.

Deinove. The second part of the phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada. 7 Apr 2022. https://www.globenewswire.com.

10.

Garey KW, McPherson J, Dinh AQ, et al. Efficacy, safety, pharmacokinetics, and microbiome changes of ibezapolstat in adults with Clostridioides difficile infection: a phase 2a multicenter clinical trial. Clin Infect Dis. 2022;75(7):1164–70.CrossRefPubMedPubMedCentral

11.

Adis Insight. Ridinilazone - Summit Therapeutics. 2022. https://adisinsight.springer.com. Accessed 31 May 2023.

12.

Acurx Pharmacueticals Inc. Clinical development program. 2023. https://www.acurxpharma.com. Accessed 31 May 23.

13.

US National Library of Medicine. Clinicaltrials.gov. 2023. https://clinicaltrials.gov/ct2/home. Accessed 20 Apr 2023.

14.

MGB Biopharma. News from MGB biopharma. 2021. https://www.prnewswire.com. Accessed 31 May 2023.

15.

Hind C, Clifford M, Woolley C, et al. Insights into the spectrum of activity and mechanism of action of MGB-BP-3. ACS Infect Dis. 2022;8(12):2552–63.CrossRefPubMedPubMedCentral

16.

Garey KW, Rose W, Wilcox MH, et al. Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence. Ann Pharmacother. 2023;57(2):184–92.CrossRefPubMed

17.

ClinicalTrials.gov. Effects of intravenous (IV) omadacycline on gut microbiome. 2023. https://clinicaltrials.gov. Accessed 31 May 2023.

18.

Ehrhardt S, Guo N, Hinz R, et al. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis. 2016;3(1):ofw011.CrossRefPubMedPubMedCentral

19.

Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–16.CrossRefPubMedPubMedCentral

20.

US Food and Drug Administration. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies: guidance for industry. 2022. https://www.fda.gov. Accessed 31 May 2023.

21.

Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220–9.CrossRefPubMed

22.

Finch Therapeutics. Finch Therapeutics announces decision to discontinue phase 3 trial of CP101 and focus on realizing the value of its intellectual property estate and other assets. 24 Jan 2023. https://ir.finchtherapeutics.com.

23.

Merck Sharp & Dohme LLC. ZINPLAVA - bezlotoxumab injection, solution: US prescribing information. 2016. https://dailymed.nlm.nih.gov. Accessed 31 May 23.

24.

Ferring Pharmaceuticals Inc. REBYOTA - donor human stool suspension: US prescribing information. 2022. https://dailymed.nlm.nih.gov. Accessed 31 May 2023.

25.

Seres Therapeutics Inc. VOWST (fecal microbiota spores, live-brpk) capsules: US prescribing information. 2023. https://www.serestherapeutics.com. Accessed 31 May 2023.

26.

Combacte-Net. Da Volterra receives first authorizations from regulatory authorities in EU countries to initiate its phase 3 clinical trial evaluating the microbiome protector DAV132 in patients with hematologic malignancies. 3 Feb 2021. https://www.combacte.com.

27.

Vehreschild M, Ducher A, Louie T, et al. An open randomized multicentre phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. J Antimicrob Chemother. 2022;77(4):2255–65.CrossRef

28.

Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305–17.CrossRefPubMed

29.

Madoff SE, Urquiaga M, Alonso CD, et al. Prevention of recurrent Clostridioides difficile infection: a systematic review of randomized controlled trials. Anaerobe. 2020;61: 102098.CrossRefPubMed

30.

Pfizer Inc. Phase 3 CLOVER trial for Pfizer’s investigational Clostridioides difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints. 1 Mar 2022. https://www.pfizer.com/news.

31.

Bezay N, Ayad A, Dubischar K, et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585–92.CrossRefPubMed

Title: Consider new therapies for the treatment and prevention of Clostridioides difficile infection
Authors: Caroline Fenton
Connie Kang
Publication date: 07-07-2023
Publisher: Springer International Publishing
Keywords: Clostridioides Difficile
Antibiotic
Published in: Drugs & Therapy Perspectives / Issue 7/2023
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.1007/s40267-023-01006-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Consider new therapies for the treatment and prevention of Clostridioides difficile infection

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2023

First reports of adverse drug reactions

Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use

All-round approaches to increase adverse drug reaction reports: a scoping review

Manage seborrhoeic dermatitis in older adults with customised regimens that address age-related factors

Age is just a number with ulcerative colitis therapies